This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ADSTILADRIN
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
ASCO 2020
ASCO 2020
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular and Penile Cancer
Press Releases
ASCO 2020 Prostate Cancer
Viewing 1-20 of 71 articles
ASCO 2020: A Phase II Study of M6620 in Combination with Carboplatin Compared with Docetaxel in Combination with Carboplatin in Metastatic Castration-Resistant Prostate Cancer
ASCO 2020: Evaluation of a Mainstream Model of Genetic Testing for Men with Prostate Cancer
ASCO 2020: Genitourinary Cancers Highlights – Prostate, Testicular, and Penile Cancers
ASCO 2020: Short-Term Adjuvant Versus Neoadjuvant Hormone Therapy in Localized Prostate Cancer: A Pooled Individual Patient Analysis of Two Phase III Trials
ASCO 2020: CYCLONE 2: A Phase II, Randomized, Placebo-Controlled Study of Abiraterone Acetate plus Prednisone with or Without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer
ASCO 2020: Quality of Life for the Treatment Sequence of Abiraterone Acetate plus Prednisone Followed by Enzalutamide Versus the Opposite Sequence for Metastatic Castration-Resistant Prostate Cancer: Results from a Phase II Randomized Clinical Trial
ASCO 2020: Association Between BRCA2 Status and Histologic Variants Intraductal and Cribriform Histology in Prostate Cancer
ASCO 2020: Clinical Outcomes and Markers of Treatment Response in a Randomized Phase II Study of Androgen Deprivation Therapy with or Without Palbociclib in RB-Intact Metastatic Hormone-Sensitive Prostate Cancer
ASCO 2020: Discussant: Promising Therapeutic Targets in Prostate Cancer
ASCO 2020: Overall Survival Results of Phase III ARAMIS Study of Darolutamide Added to Androgen Deprivation Therapy for Non-metastatic Castration-Resistant Prostate Cancer
ASCO 2020: Cost-Effectiveness of Novel Antiandrogens for Treatment of Nonmetastatic Castrate-Resistant Prostate Cancer
ASCO 2020: Discussant: Advanced Prostate Cancer: Putting Survival Into Perspective
ASCO 2020: Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study: A Canadian Cancer Trials Group Phase 2 Umbrella Trial for MCRPC (IND223/IND224)
ASCO 2020: Ensuring Cancer Research Progress During a Global Pandemic
ASCO 2020: Looking Back on COVID-19 in Order to Move Forward
ASCO 2020: TERAVOLT – Thoracic Cancers International COVID-19 Collaboration: Impact of Cancer Therapy and COVID-19 Therapy on Survival
ASCO 2020: Safety Outcomes of Darolutamide Versus Apalutamide and Enzalutamide in nmCRPC: Matching-Adjusted Indirect Comparisons
ASCO 2020: Cabazitaxel vs. Enazlutamide/arbiraterone in CARD Eligible mCRPC Patients with or Without Germline HRR Defects
ASCO 2020: Cancer Care in the Time of COVID: Assessing Impact and Future Directions
ASCO 2020: Molecular Determinants of Outcome for Metastatic Castration-Sensitive Prostate Cancer with Addition of Apalutamide or Placebo to Androgen Deprivation Therapy in TITAN
1
2
3
4
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free